Skip to main content
Erschienen in: Discover Oncology 1/2010

01.02.2010

Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen

verfasst von: S. John Weroha, Wilma L. Lingle, Yan Hong, Sara Antonia Li, Jonathan J. Li

Erschienen in: Discover Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Overexpressed Aurora A, amplified centrosomes, and aneuploidy are salient features of estrogen-induced mammary preinvasive lesions and tumors in female August–Copenhagen Irish (ACI) rats. Intimately involved in these events are cyclins and their associated cyclin-dependent kinase (CDK) partners. Cyclin E1·CDK2 overexpression plays an important dual role in late G1/S phase of the cell cycle in cancer cells. It increases DNA replication providing growth advantage to cancer cells and facilitates aberrant centrosome duplication, generating chromosomal instability and aneuploidy leading to tumor development. Presented herein, a 24.0- and 45.0-fold elevation in cyclin E1 and CDK2 was found in 17β-estradiol (E2)-induced ACI rat mammary tumors (MTs), respectively. Cyclin E·CDK2 positive staining was confined to the large round cells found within focal dysplasias, ductal carcinomas in situ, and invasive MTs. Co-immunoprecipitation and in vitro kinase activity of these tumors revealed that these cell cycle entities are functional. When mammary tissue derived from untreated normal, E2-induced hyperplasia and primary tumors were normalized to cyclin E1 levels, low molecular weight (LMW) cyclin E1 forms (33- and 45-kDa) were detected in all of these tissue groups. Moreover, increasing concentrations of protease inhibitor in tissue lysates resulted in a marked reduction of LMW forms, indicating that the presence of cyclin E1 LMW forms can be markedly reduced. Significant increases in cyclin E1 mRNA (2.1-fold) were detected in primary ACI rat E2-induced breast tumors, and quantitative real-time polymerase chain reaction revealed a 20% amplification of the cyclin E1 gene (CCNE1). Collectively, these results support the involvement of cyclin E1·CDK2 in centrosome overduplication during each stage of E2-induced mammary tumorigenesis.
Literatur
1.
Zurück zum Zitat The American Cancer Society (2008) Cancer facts & figures 2008. The American Cancer Society, New York The American Cancer Society (2008) Cancer facts & figures 2008. The American Cancer Society, New York
2.
Zurück zum Zitat Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439–443CrossRefPubMed Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439–443CrossRefPubMed
3.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Oncogene. 2008 Feb 21; 27(9):1253-1262. Program (www.seercancer.gov) SEER*Stat, Database: Incidence- SEER17 Reqs Limited-Use, Nov. 2006 Sub (2000-2004) Linked to County, Attributes- Total US 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance, Research Program, Cancer Statistics Branch, released April 2007. Based on the November 2006 submission Surveillance, Epidemiology, and End Results (SEER) Oncogene. 2008 Feb 21; 27(9):1253-1262. Program (www.​seercancer.​gov) SEER*Stat, Database: Incidence- SEER17 Reqs Limited-Use, Nov. 2006 Sub (2000-2004) Linked to County, Attributes- Total US 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance, Research Program, Cancer Statistics Branch, released April 2007. Based on the November 2006 submission
4.
Zurück zum Zitat Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, Krook JE, Wieand HS (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78:764–772CrossRefPubMed Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, Krook JE, Wieand HS (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78:764–772CrossRefPubMed
5.
Zurück zum Zitat Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28–34CrossRefPubMed Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28–34CrossRefPubMed
6.
Zurück zum Zitat Arnerlov C, Emdin SO, Cajander S, Bengtsson NO, Tavelin B, Roos G (2001) Intratumoral variations in DNA ploidy and s-phase fraction in human breast cancer. Anal Cell Pathol 23:21–28PubMed Arnerlov C, Emdin SO, Cajander S, Bengtsson NO, Tavelin B, Roos G (2001) Intratumoral variations in DNA ploidy and s-phase fraction in human breast cancer. Anal Cell Pathol 23:21–28PubMed
7.
Zurück zum Zitat Wiesener B, Hauser-Kronberger CE, Zipperer E, Dietze O, Menzel C, Hacker GW (1998) p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression. Histopathology 33:522–530CrossRefPubMed Wiesener B, Hauser-Kronberger CE, Zipperer E, Dietze O, Menzel C, Hacker GW (1998) p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression. Histopathology 33:522–530CrossRefPubMed
8.
Zurück zum Zitat Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464CrossRefPubMed Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464CrossRefPubMed
9.
10.
Zurück zum Zitat Li JJ, Li SA (2006) Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 111:974–984CrossRefPubMed Li JJ, Li SA (2006) Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 111:974–984CrossRefPubMed
11.
Zurück zum Zitat Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59:2041–2044PubMed Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59:2041–2044PubMed
12.
Zurück zum Zitat Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978–1983CrossRefPubMed Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978–1983CrossRefPubMed
13.
Zurück zum Zitat Perez-Roger I, Solomon DL, Sewing A, Land H (1997) Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14:2373–2381CrossRefPubMed Perez-Roger I, Solomon DL, Sewing A, Land H (1997) Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14:2373–2381CrossRefPubMed
14.
Zurück zum Zitat Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL (2008) Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 630:189–205CrossRefPubMed Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL (2008) Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 630:189–205CrossRefPubMed
15.
Zurück zum Zitat Fukasawa K (2008) P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta 1786:15–23PubMed Fukasawa K (2008) P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta 1786:15–23PubMed
16.
Zurück zum Zitat Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G (1999) Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283:851–854CrossRefPubMed Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G (1999) Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283:851–854CrossRefPubMed
17.
Zurück zum Zitat Matsumoto Y, Hayashi K, Nishida E (1999) Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 9:429–432CrossRefPubMed Matsumoto Y, Hayashi K, Nishida E (1999) Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 9:429–432CrossRefPubMed
18.
Zurück zum Zitat Ferguson RL, Maller JL (2008) Cyclin E-dependent localization of MCM5 regulates centrosome duplication. J Cell Sci 121:3224–3232CrossRefPubMed Ferguson RL, Maller JL (2008) Cyclin E-dependent localization of MCM5 regulates centrosome duplication. J Cell Sci 121:3224–3232CrossRefPubMed
19.
Zurück zum Zitat Duensing A, Liu Y, Perdreau SA, Kleylein-Sohn J, Nigg EA, Duensing S (2007) Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene 26:6280–6288CrossRefPubMed Duensing A, Liu Y, Perdreau SA, Kleylein-Sohn J, Nigg EA, Duensing S (2007) Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene 26:6280–6288CrossRefPubMed
20.
Zurück zum Zitat Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE et al (2000) Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103:127–140CrossRefPubMed Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE et al (2000) Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103:127–140CrossRefPubMed
21.
Zurück zum Zitat Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD (2002) CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 3:339–350CrossRefPubMed Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD (2002) CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 3:339–350CrossRefPubMed
22.
Zurück zum Zitat Fisk HA, Winey M (2001) The mouse Mps1p-like kinase regulates centrosome duplication. Cell 106:95–104CrossRefPubMed Fisk HA, Winey M (2001) The mouse Mps1p-like kinase regulates centrosome duplication. Cell 106:95–104CrossRefPubMed
23.
Zurück zum Zitat Nishimura T, Takahashi M, Kim HS, Mukai H, Ono Y (2005) Centrosome-targeting region of CG-NAP causes centrosome amplification by recruiting cyclin E-cdk2 complex. Genes Cells 10:75–86CrossRefPubMed Nishimura T, Takahashi M, Kim HS, Mukai H, Ono Y (2005) Centrosome-targeting region of CG-NAP causes centrosome amplification by recruiting cyclin E-cdk2 complex. Genes Cells 10:75–86CrossRefPubMed
24.
Zurück zum Zitat Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, Raff JW (2008) Centrosome amplification can initiate tumorigenesis in flies. Cell 133:1032–1042CrossRefPubMed Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, Raff JW (2008) Centrosome amplification can initiate tumorigenesis in flies. Cell 133:1032–1042CrossRefPubMed
25.
Zurück zum Zitat Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, El-Bayoumy K, Ballenger J, Tawfik O, Li SA (2002) Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog 33:56–65CrossRefPubMed Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, El-Bayoumy K, Ballenger J, Tawfik O, Li SA (2002) Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog 33:56–65CrossRefPubMed
26.
Zurück zum Zitat Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 101:18123–18128CrossRefPubMed Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 101:18123–18128CrossRefPubMed
27.
Zurück zum Zitat Li JJ, Li SA (2007) Deciphering the conundrum of estrogen-driven breast cancer: Aurora kinase deregulation. In: Melmed SRH, Chanson P, Christen Y (eds) Hormonal control of cell cycle. Springer, Heidelberg, pp 49–62 Li JJ, Li SA (2007) Deciphering the conundrum of estrogen-driven breast cancer: Aurora kinase deregulation. In: Melmed SRH, Chanson P, Christen Y (eds) Hormonal control of cell cycle. Springer, Heidelberg, pp 49–62
28.
Zurück zum Zitat Baker GL, Landis MW, Hinds PW (2005) Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 4:330–338PubMed Baker GL, Landis MW, Hinds PW (2005) Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 4:330–338PubMed
29.
Zurück zum Zitat Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, Stanley MW, Albrecht JH (2005) Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280:768–776PubMed Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, Stanley MW, Albrecht JH (2005) Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280:768–776PubMed
30.
Zurück zum Zitat Page DL, Dupont WD (1990) Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66:1326–1335CrossRefPubMed Page DL, Dupont WD (1990) Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66:1326–1335CrossRefPubMed
31.
Zurück zum Zitat Spruck C, Sun D, Fiegl H, Marth C, Mueller-Holzner E, Goebel G, Widschwendter M, Reed SI (2006) Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66:7355–7360CrossRefPubMed Spruck C, Sun D, Fiegl H, Marth C, Mueller-Holzner E, Goebel G, Widschwendter M, Reed SI (2006) Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66:7355–7360CrossRefPubMed
32.
Zurück zum Zitat Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208CrossRefPubMed Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208CrossRefPubMed
33.
Zurück zum Zitat Bodin L, Beaune PH, Loriot MA (2005) Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol 3:248–253CrossRef Bodin L, Beaune PH, Loriot MA (2005) Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol 3:248–253CrossRef
34.
Zurück zum Zitat Weroha SJ, Li SA, Tawfik O, Li JJ (2006) Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis 27:491–498CrossRefPubMed Weroha SJ, Li SA, Tawfik O, Li JJ (2006) Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis 27:491–498CrossRefPubMed
35.
Zurück zum Zitat Wang X-J, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Toop DR (1998) Analysis of centrosome abnormalities and angiogenesis in epidermal-target p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinogenesis 23:185–192CrossRef Wang X-J, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Toop DR (1998) Analysis of centrosome abnormalities and angiogenesis in epidermal-target p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinogenesis 23:185–192CrossRef
36.
Zurück zum Zitat Neben K, Tews B, Wrobel G, Hahn M, Kokocinski F, Giesecke C, Krause U, Ho AD, Kramer A, Lichter P (2004) Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene 23:2379–2384CrossRefPubMed Neben K, Tews B, Wrobel G, Hahn M, Kokocinski F, Giesecke C, Krause U, Ho AD, Kramer A, Lichter P (2004) Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene 23:2379–2384CrossRefPubMed
37.
Zurück zum Zitat Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D (1999) Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18:1983–1991CrossRefPubMed Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D (1999) Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18:1983–1991CrossRefPubMed
38.
Zurück zum Zitat Bartkova J, Zemanova M, Bartek J (1996) Abundance and subcellular localisation of cyclin D3 in human tumours. Int J Cancer 65:323–327CrossRefPubMed Bartkova J, Zemanova M, Bartek J (1996) Abundance and subcellular localisation of cyclin D3 in human tumours. Int J Cancer 65:323–327CrossRefPubMed
39.
Zurück zum Zitat Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380–385PubMed Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380–385PubMed
40.
Zurück zum Zitat Scott KA, Walker RA (1997) Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer 76:1288–1292PubMed Scott KA, Walker RA (1997) Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer 76:1288–1292PubMed
41.
Zurück zum Zitat Keyomarsi K, Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90:1112–1116CrossRefPubMed Keyomarsi K, Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90:1112–1116CrossRefPubMed
42.
Zurück zum Zitat Enders GH (2002) Cyclins in breast cancer: too much of a good thing. Breast Cancer Res 4:145–147CrossRefPubMed Enders GH (2002) Cyclins in breast cancer: too much of a good thing. Breast Cancer Res 4:145–147CrossRefPubMed
43.
Zurück zum Zitat Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C (1996) Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247–253CrossRefPubMed Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C (1996) Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247–253CrossRefPubMed
44.
Zurück zum Zitat Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S et al (2003) Cyclin E overexpression and amplification in human tumours. J Pathol 200:375–382CrossRefPubMed Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S et al (2003) Cyclin E overexpression and amplification in human tumours. J Pathol 200:375–382CrossRefPubMed
45.
Zurück zum Zitat Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413:316–322CrossRefPubMed Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413:316–322CrossRefPubMed
Metadaten
Titel
Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen
verfasst von
S. John Weroha
Wilma L. Lingle
Yan Hong
Sara Antonia Li
Jonathan J. Li
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Discover Oncology / Ausgabe 1/2010
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-009-0004-z

Weitere Artikel der Ausgabe 1/2010

Discover Oncology 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.